Pliva, Eastern Europe's biggest drug maker by sales, saw its
profits take a massive dive in the first quarter of 2006, as a huge
loss of royalties could not be offset by the relatively small
growth in its generics business.
Reforms do not come cheap, certainly not for Croatian
pharmaceutical company Pliva, whose strategy of abandoning its
proprietary drugs in favour of generics may pay off in the long
term, but, along with manufacturing consolidation...
A one-dose, microsphere formulation of azithromycin is as effective
as several days' treatment with other drugs for respiratory tract
infections (RTIs), according to new clinical data.
Pliva has continued its rapid expansion with the opening of a new
R&D facility in the USA that will carry out formulation work on
generic pharmaceuticals.